Is It Time to Buy Altcoins? 3 High-Potential Infrastructure Projects Poised to Outperform Chainlink

The  market is heavily influenced by broader geopolitical and economic factors, particularly the ongoing tensions in the Middle East and upcoming U.S.

The cryptocurrency market remained largely stagnant on Monday evening, with Bitcoin showing minimal price movements and key levels yet to be breached for a clear bullish or bearish trend.

Bitcoin was trading at $60,243 at the time of writing, according to CoinMarketCap, having seen a slight decrease of 0.07% over the past 24 hours. The world’s largest cryptocurrency had a trading volume of over $40 billion in the past 24 hours.

The market is heavily influenced by broader geopolitical and economic factors, particularly the ongoing tensions in the Middle East and upcoming U.S. economic data.

Despite some minor price movements, Bitcoin hasn’t shown significant momentum, with key levels at $62,400 needing to be reclaimed for a bullish trend. However, if the price drops below $60,000, a further decline toward $58,000 is possible.

But there is one question looming on everyone’s mind— is it the right time to buy altcoins?

In the latest analysis by Altcoin Buzz, the analyst listed three high-potential infrastructure projects, poised to outperform Chainlink.

Altcoin 1: Cheqd (CHEQ)

Cheqd is focused on creating a decentralized infrastructure for identity management and data ownership. Frasier Edwards, Cheqd’s CEO, recently brought to attention the increasing demand for decentralized ID solutions, especially given the ongoing issues with data privacy and integrity.

Cheqd aims to build use cases that demonstrate the value of decentralized identities, positioning itself as a leader in this sector.

Edwards highlighted the importance of self-sovereign identity (SSI) in the digital age, where individuals should have complete control over their personal data and decide who can access it.

He further noted that decentralized IDs are crucial for emerging technologies like Web3 and the metaverse.

Cheqd’s token, CHEQ, has seen a remarkable surge of over 350% since the beginning of 2023. It currently trades at $0.42, following a slight dip of 0.82% over the past 24 hours.

Edwards’ statement comes amid increasing regulatory scrutiny and legal battles surrounding centralized digital identity providers, such as Clearview AI and LexisNexis.

The demand for decentralized and privacy-preserving solutions is expected to continue rising as people become more aware of the risks associated with centralized data management.

Altcoin 2: Peak (PEAQ)

Peaq is a decentralized physical infrastructure network (DePIN) project that aims to reshape how data is collected, stored and utilized.

The project combines decentralized data control with privacy, which is essential for gaining higher adoption rates in Web 3.

According to Co-founder Leonard Doorlocker, privacy is paramount in Web 3, andリューマチ性疾患の治療に役立つ可能性のある新しい抗体医薬品候補を特定したと発表した。候補物質は、インターロイキン（IL）-17A と IL-17F を標的とするモノクローナル抗体で、関節リウマチ（RA）や乾癬性関節炎（PsA）などの自己免疫疾患の治療に役立つ可能性があるという。

候補物質は、ヒト末梢血単核球（PBMC）から単離した B 細胞を、IL-17A または IL-17F を発現する細胞株と融合させて作製した。融合細胞は、IL-17A または IL-17F に結合する抗体を産生するハイブリドーマに増殖させ、抗体は精製してモノクローナル抗体として評価した。

候補物質は、IL-17A または IL-17F に対して高い親和性を示し、細胞株やヒト PBMC 由来の細胞から産生される IL-17A または IL-17F を強力に中和した。また、候補物質は、RA や PsA の病態生理に関与する炎症性サイトカインやケモカインの産生を抑制した。

さらに、候補物質は、コラーゲン誘発性関節炎（CIA）マウスモデルにおいて、関節炎の重症度を有意に軽減し、骨破壊を抑制した。候補物質は、CIA マウスの末梢血中 IL-17A レベルを低下させ、滑膜組織における IL-17A 陽性細胞の浸潤を抑制した。

これらの結果は、IL-17A と IL-17F を標的とするモノクローナル抗体候補物質が、RA や PsA の治療に役立つ可能性があることを示唆している。候補物質は、現在、前臨床試験が進められており、今後、ヒトでの臨床試験が計画されている。

The above is the detailed content of Is It Time to Buy Altcoins? 3 High-Potential Infrastructure Projects Poised to Outperform Chainlink. For more information, please follow other related articles on the PHP Chinese website!